A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 weeks of Treatment with Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis

Study identifier:322

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 weeks of Treatment with Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis.

Medical condition

Erosive Esophagitis

Phase

Phase 4

Healthy volunteers

Study drug

Esomeprazole, Lansoprazole

Sex

All

Actual Enrollment

1000

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Dec 2002

Primary Completion Date: 01 Aug 2003

Study Completion Date: 01 Aug 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Nexium	Drug: Esomeprazole 40mg once daily Other Name: Nexium
Active Comparator: 2 Prevacid	Drug: Lansoprazole 30mg once daily Other Name: Prevacid

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1161&filename=CSR-322.pdf
Download
CSR-322.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Paula Fernstrom

Nexium Global Product Director, AstraZeneca